Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stephanie Graebert

Pediatrics Metairie, LA Medical Doctor

NPI 1003202581 CMS profile 4798630

4224 Houma Blvd Ste 240, Metairie, LA 70006

Open in the dashboard

General payments

$2,438

113 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stephanie Graebert of Metairie, LA is reported in the CMS Open Payments database as having received $2,438 across 113 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $503 21
2024 General $708 21
2023 General $285 15
2022 General $167 10
2021 General $312 16
2020 General $279 16
2019 General $184 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephanie Graebert
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Stephanie Graebert were reported at $503. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Stephanie Graebert Pediatrics median Middle half National median
2019 $184 $86 $31–$183 $163
2020 $279 $49 $22–$110 $114
2021 $312 $68 $27–$158 $132
2022 $167 $77 $30–$173 $149
2023 $285 $88 $33–$190 $160
2024 $708 $94 $34–$206 $164
2025 $503 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Supernus Pharmaceuticals, Inc. $717 15 payments
  2. Corium, Inc. $244 14 payments
  3. Tris Pharma Inc $219 13 payments
  4. GlaxoSmithKline, LLC. $209 12 payments
  5. Ironshore Pharmaceuticals Inc. $182 8 payments
  6. Pfizer Inc. $161 8 payments
  7. Merck Sharp & Dohme Corporation $152 10 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $81 6 payments
  9. Kowa Pharmaceuticals America, Inc. $47 3 payments
  10. Cranial Technologies, Inc $43 3 payments
  11. Other $382 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,438 113 payments
Products named General payments · program years 2019–2025
  1. Qelbree Viloxazine Hydrochloride $586 10 payments
  2. Azstarys $244 14 payments
  3. BEXSERO $192 11 payments
  4. COMIRNATY $132 6 payments
  5. QELBREE Psychology $131 5 payments
  6. GARDASIL 9 $129 8 payments
  7. PREVNAR 20 $115 5 payments
  8. VAXELIS $97 6 payments
  9. JORNAY PM $92 4 payments
  10. TRUMENBA $89 4 payments
  11. Other $1,349 78 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

113 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record